Polypill cuts CVD risk by one-third
Largest trial to date shows four in one pill effective for primary prevention: study
A polypill combining four cardiovascular drugs cut the risk of major cardiovascular events by a third over five years, a Lancet study finds.
The study looked at the effectiveness of the four-in-one pill in primary and secondary prevention of CVD in rural Iran.
Researchers found those taking the pill had a 34% lower risk of a CVD event, than those just offered advice, over the five years of the study.
Researchers compared the effect of the polypill — containing aspirin, atorvastatin, hydrochlorothiazide, and either enalapril or valsartan — and lifestyle advice alone in more than 6800 people aged 50-75.
